🔴 GT Biopharma is trading 10.57% down today with no definitive catalyst identified

GT Biopharma is trading at $0.25, down -10.57%, with no definitive catalyst identified.

• No dated company announcement, SEC filing, earnings release, or clinical update explains the September 3, 2026 decline.
• Broader equities and biotech moved higher, making market-wide sentiment an unlikely explanation; a Zacks Buy upgrade appeared September 3 but did not support the decline or provide a clear negative catalyst.
• The move most likely reflects speculative or technical selling, though no definitive cause was identified.